Carasent AB (publ) (CARA) Earnings Call Transcripts

Carasent AB (publ)'s Latest Earnings Call - Q1 FY2026

In Q1 2026, Carasent AB reported a revenue of SEK 90.4 million, reflecting a 6% increase year-over-year, driven by a robust 16% growth in Annual Recurring Revenue (ARR) to SEK 360 million. The company's EBITDAC margin improved to 10%, up from 6% a year ago, indicating effective cost management despite a significant drop in consulting revenues. Management maintained a positive outlook for ARR growth, particularly in the Nordics, while signaling challenges in the German market due to legacy product churn. Guidance for the upcoming quarters suggests a focus on scaling the new Webcur system in Germany and leveraging AI capabilities to enhance product offerings.

Reported metrics

Guidance from management

Management expects continued strong organic growth in the Nordics while acknowledging challenges in Germany. They aim to launch Webcur and enhance AI functionalities by the end of the year, with a focus on maintaining cost discipline.

What management said

Yes, sure. So I would say that the Q1 is a bit on the weaker side on consulting than like a normal level because we didn't have Metodika doing a lot of consulting work. But in general, it's not the key priority for us, as we mentioned. It's not that simple to be very specific on like guiding for the next quarter and the year. But I would say, in Q1, it's a bit lower than what we have as a run rate level when Metodika...

Yes, I think that's a bit too early. So this year, it will probably continue more or less in that trend, I would say. And the major thing to look at this year is to really get Webcur up and running, happy customers, the first ones who can be references for future customers that we get sales and marketing going and so on, but for them during next year and the year after that to really see growth coming and that we're ...

What analysts pressed on

Analysts expressed concerns regarding the decline in consulting revenues and the potential for ongoing churn in the German market. There were questions about the pace of customer adoption for new AI features and the impact of these developments on overall growth.

Main topics on the call

• Strong ARR Growth — Carasent achieved a 16% year-over-year growth in ARR, reaching SEK 360 million, with a net revenue retention rate of 111%. CEO Daniel Ohman emphasized, "We continue to scale our business in a good way," highlighting the ...
• Decline in Consulting Revenues — Consulting revenues fell by 50% from SEK 8 million to SEK 4 million, impacting overall revenue growth. CFO Svein Bjornstad noted, "Consulting revenues typically vary more from quarter-to-quarter and is more lumpy in natu...
• AI Integration and Product Development — The company is focusing on integrating AI into its products, particularly with Medsum, which aims to streamline administrative tasks for healthcare providers. Ohman stated, "We believe strongly that as it gets fast and f...
• Challenges in the German Market — Management acknowledged ongoing challenges in Germany, with a third of churn attributed to legacy products. Ohman commented, "It will probably continue more or less in that trend," suggesting a cautious outlook for immed...

Read the full Carasent AB (publ) transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 6 Carasent AB (publ) earnings call transcripts on record, spanning February 13, 2025 to July 10, 2026. Based on this history, Carasent AB (publ) reports quarterly. The most recent call on file is dated July 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CARA

Exchange

OM

Country

SE

Sector

Health Care

Industry

Health Care Technology

Calls on record

6

First call

February 13, 2025

Most recent

July 10, 2026

Reporting cadence

quarterly